

Remarks

Applicants respectfully request this preliminary amendment be entered before consideration of the application on the merits. The present application is a divisional of U.S. Serial No. 10/327,385, which now stands allowed.

1. **Status of the Claims**

In the above amendment, Claims 1-21 have been canceled, Claim 22 has been amended, and new Claims 23-33 have been added. Upon entry of the above amendments, Claims 22-33 are pending in this application.

2. **Amendments to the Specification**

The specification has been amended on page 1 to claim priority to parent application U.S. Serial No. 10/327,385.

The specification has been amended on pages 2, 3, 8, 9, 10, and twice on page 11, to explicitly include the hydrogen atoms bonded to the nitrogen atoms of the ring systems in formulas (I), (Ia), (II), (IV), (VI), (VII), and (VIII). These amendments correct obvious errors in the depiction of the chemical structures. No new matter has been added. Entry of the amendments to the specification is respectfully requested.

3. **Amendments to the Claims**

Please cancel Claims 1-21 without prejudice or disclaimer with Applicants reserving the right to pursue the subject matter of the canceled claims in a separate application.

Claim 22 has been amended to claim a method of treatment utilizing a compound of Formula (Ia) and is supported, at least, at page 8, lines 23-26 of the specification as filed. Claims 23 and 24 are to a method of treatment based on specific compounds, and are supported by, for example, original Claims 16 and 17.

Claims 25-27 are directed to a method of treatment of conditions responsive to a tyrosine kinase inhibitor, such as proliferative disorders, for example, forms of cancer, and are supported,

for example, at page 3, lines 21-23; page 9, lines 15-19; and page 27, line 15 through page 28 line 16 of the specification as filed.

Newly added Claim 28 is to a method of treatment based on a pharmaceutical composition comprising compounds of formula (Ia) and a pharmaceutically acceptable diluent or carrier. Support for Claim 28 is found in the specification, at the passages cited above, and, in addition, at page 4, lines 2-4; page 12, line 8 through the bottom of page 15, and in original Claims 19 and 20. Claims 30-33 are supported in the specification as described above for Claims 25-28.

No new matter has been added. Entry of the amendments to the claims is respectfully requested.

Applicants respectfully request further processing of this application. Should the Examiner wish to discuss any aspect of the present application, the Examiner is invited to telephone the undersigned Agent for Applicants at (650) 808-3764.

Respectfully submitted,

Date: October 22, 2003

By: Roberta P. Saxon
Roberta P. Saxon, Ph.D.
Reg. No. 43,087

THERAVANCE, INC.
901 Gateway Boulevard
South San Francisco, CA 94080
Tel: (650) 808-6000
Fax: (650) 808-6078